Navigation Links
InVitria Announces Launch of Recombinant Albumin for Diagnostics
Date:4/17/2009

Fort Collins, CO, April 17, 2009 / b3c newswire / - Addressing significant product safety and consistency issues in the human diagnostics market, InVitria has announced the commercial launch of two protease-free recombinant albumin products. InVitria’s Recombinant Albumin-DX and Recombinant Albumin-DX (Lipid-Free) perform better in diagnostics applications than both bovine serum albumin (BSA) and plasma-derived human serum albumin (pHSA). 
  • The advantages of Recombinant Albumin-DX include:
  • Reduce non-specific binding and improve specificity;
  • Improved consistency due to recombinant manufacturing;
  • Improved stabilization of sensitive proteins and biomarkers; and
  • Reduce occupational safety risk and regulatory burden of handling human or animal blood products.
Customer testing has shown that Recombinant Albumin-DX (Lipid-Free) increased biomarker activity to levels twice as high as the current commercial alternative. In addition, stability over time was significantly improved with Recombinant Albumin-DX (Lipid-Free). Tests have also shown the bioequivalence of the Recombinant Albumin-DX to native human serum albumin (HSA).  
 
“InVitria is committed to developing high performance, regulatory friendly products for the diagnostics market and our Recombinant Albumin-DX and DX Lipid-Free products deliver on this promise,” said the company’s President and CEO Scott Deeter. “Recombinant Album-DX and DX Lipid-Free provide the specificity, stability and consistency that diagnostic customers seek.”
 
To receive a Recombinant Albumin-DX or DX Lipid-Free product materials packet, please contact InVitria’s customer service specialists at 1-800-916-8311 or by e-mail at info@InVitria.com.
ws" timex="4/17/2009 5:26:57 AM" dirsub="(bsp; About InVitria InVitria develops ...)" id="8019" index="biology" dir="InVitria Announces Launch of Recombinant Albumin for Diagnostics" dir2="InVitria Announces Launch of Recombinant Albumin for D..." keywords1=",biological,biology news articles,biology news today,latest biology news,current biology news,biology newsletters" keywords="InVitria,Announces,Launch,of,Recombinant,Albumin,for,Diagnostics" description="bsp; About InVitria InVitria develops manufactures and markets a portfolio of cell culture and diagnostic reagents. These products are used in cell culture biopharmaceutical formulation stem cell & regenerative medicine medical devices and diagnostics.   Learn more about InVitria’s products at a target _blank href http://www.in" url=u&"/biology-news-1/InVitria-Announces-Launch-of-Recombinant-Albumin-for-Diagnostics-8019-2/" title="InVitria%20Announces%20Launch%20of%20Recombinant%20Albumin%20for%20Diagnostics" %> InVitria Announces Launch of Recombinant Albumin for D... (Fort Collins CO April 17 2009 / b3c news...)
InVitria Announces Launch of Recombinant Albumin for Diagnostics
Date:4/17/2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/20/2017)... , March 20, 2017 At this year,s ... -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand ... is this year,s CeBIT partner country. At the largest German biometrics ... in use: fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics ... ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... , April 25, 2017 ... ("EpiVax") has licensed its novel immune-modulating technology to an ... disease and allergy. Tregitopes, pronounced T·rej·itopes, ... human immunoglobulin by EpiVax CEO Annie De ... to intravenous immunoglobulin G, an autoimmune disease therapy, ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Partners.     , Covalent’s Analytical Services unit provides high-quality data to clients, ... within 24 hours of receipt. There are no price premiums, and customers are ...
(Date:4/24/2017)... ... April 24, 2017 , ... It ... a cellular milieu; however, the broad application of this cellular target engagement concept ... sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for particular applications, ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... manufactures in 10 categories with over 30 nominees and well as the first-year ... the new award and the event was hosted by CompanyWeek and Manufacturers Edge, ...
Breaking Biology Technology: